Prediction of histologic differentiation grade of hepatocellular carcinoma by magnetic resonance imaging with hepatospecific contrast agent

Background: To evaluate the predictive value at the hepatobiliary phase (HBP) magnetic resonance imaging (MRI) after gadobenate dimeglumine (GdBOPTA) injection for histologic grades of hepatocellular carcinoma (HCC). Materials and Methods: HCC patients who underwent Gd-BOPTA-enhanced MRI were analyzed and divided into four histologic grades of differentiation based on Edmonson-Steiner grade. Besides, HCC tumor differentiations grade I, II and III, IVwere defined as well-differentiated (WD), moderatelydifferentiated (MD), poorly-differentiated (PD), respectively. The clinical, pathological and imaging features of patients were assessed. Receiver operating characteristic (ROC) curve was to evaluate the significance between WD/MD HCC and PD HCC using the apparent diffusion coefficient (ADC), relative intensity ratio (RIR) of T1WI and T2WI (T1RIR, T2RIR), contrastenhancement ratio in arterial phase (CERA) and contrast-noise-ratio (CNR) in HBP (CNRhbp). Results: A total of 102 HCC patients were analyzed (grade I, n=19; grade II, n=30; grade III, n=30; grade IV, n=23). There was no statistical difference regarding to the pathological and clinical features among four grades. There were significant differences in CERA, CNRhbp, T1RIR, T2RIR and ADC values among the four HCC grades (all P<0.05). Based on ROC curve, comparison of the five quantitative MRI parameters indicated ADC (sensitivity 84.8%, specificity 82.6%, AUC 0.862) and CNRhbp value (sensitivity 78.5%, specificity 91.3%, AUC 0.916) could significantly distinguish the HCC histological grade. Conclusions: The ADC and/or CNRhbp value in HBP-MRI after GD-BOPTA injection might be as the significant quantitative parameters to distinguish HCC histological grade.

[1]  M. Okada,et al.  Diagnostic Value of Imaging Methods in the Histological Four Grading of Hepatocellular Carcinoma , 2020, Diagnostics.

[2]  Yuyang Jiang,et al.  Current discovery strategies for hepatocellular carcinoma therapeutics , 2019, Expert opinion on drug discovery.

[3]  Qiang Liu,et al.  Understanding the Global Cancer Statistics 2018: implications for cancer control , 2019, Science China Life Sciences.

[4]  Chenyu Song,et al.  Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation , 2019, BMC Cancer.

[5]  A. Luciani,et al.  MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio , 2019, European Radiology.

[6]  T. Pawlik,et al.  A wide‐margin liver resection improves long‐term outcomes for patients with HBV‐related hepatocellular carcinoma with microvascular invasion☆ , 2019, Surgery.

[7]  L. Roberts,et al.  Molecular and cellular oncogenic mechanisms in hepatocellular carcinoma. , 2018, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[8]  A. Luciani,et al.  Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions , 2018, European Radiology.

[9]  D. Cao,et al.  Hepatocellular Carcinoma: Retrospective Evaluation of the Correlation Between Gadobenate Dimeglumine–Enhanced Magnetic Resonance Imaging and Pathologic Grade , 2018, Journal of computer assisted tomography.

[10]  M. Mazurowski,et al.  Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma. , 2018, AJR. American journal of roentgenology.

[11]  M. Kanda,et al.  Emerging evidence of molecular biomarkers in hepatocellular carcinoma. , 2018, Histology and histopathology.

[12]  U. Tateishi,et al.  Prediction of histological grade of hepatocellular carcinoma using quantitative diffusion-weighted MRI: a retrospective multivendor study. , 2018, The British journal of radiology.

[13]  K. Cortis,et al.  Incorporating the hepatobiliary phase of gadobenate dimeglumine-enhanced MRI in the diagnosis of hepatocellular carcinoma: increasing the sensitivity without compromising specificity , 2016, Acta radiologica.

[14]  D. Lu,et al.  Gadoxetate Disodium-Enhanced MRI to Differentiate Dysplastic Nodules and Grade of Hepatocellular Carcinoma: Correlation With Histopathology. , 2015, AJR. American journal of roentgenology.

[15]  R. Cabrera,et al.  Current and future treatments for hepatocellular carcinoma. , 2015, World journal of gastroenterology.

[16]  M. Imbriaco,et al.  Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review , 2015, La radiologia medica.

[17]  W. Guo,et al.  Histological grade of hepatocellular carcinoma predicted by quantitative diffusion-weighted imaging. , 2015, International journal of clinical and experimental medicine.

[18]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[19]  B. Taouli,et al.  Hepatocellular carcinoma: Short‐term reproducibility of apparent diffusion coefficient and intravoxel incoherent motion parameters at 3.0T , 2015, Journal of magnetic resonance imaging : JMRI.

[20]  B. Choi,et al.  Intravoxel incoherent motion diffusion-weighted MR imaging of hepatocellular carcinoma: correlation with enhancement degree and histologic grade. , 2014, Radiology.

[21]  Ting-An Chang,et al.  Differentiation between dysplastic nodule and early-stage hepatocellular carcinoma: the utility of conventional MR imaging. , 2013, World journal of gastroenterology.

[22]  U. Motosugi,et al.  Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. , 2011, Radiology.

[23]  F. Akisik,et al.  Does the hepatocellular phase of gadobenate dimeglumine help to differentiate hepatocellular carcinoma in cirrhotic patients according to histological grade? , 2011, Clinical radiology.

[24]  D. Choi,et al.  Gadoxetic Acid (Gd-EOB-DTPA)-Enhanced MRI versus Gadobenate Dimeglumine (Gd-BOPTA)-Enhanced MRI for Preoperatively Detecting Hepatocellular Carcinoma: an Initial Experience , 2010, Korean journal of radiology.

[25]  W. Lau,et al.  Partial Hepatectomy With Wide Versus Narrow Resection Margin for Solitary Hepatocellular Carcinoma: A Prospective Randomized Trial , 2007, Annals of surgery.

[26]  W. Coleman,et al.  Mechanisms of human hepatocarcinogenesis. , 2003, Current molecular medicine.

[27]  H. Edmondson,et al.  Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies , 1954, Cancer.

[28]  H. Honda,et al.  Arterial blood supply of hepatocellular carcinoma and histologic grading: radiologic-pathologic correlation. , 2008, AJR. American journal of roentgenology.

[29]  S. Arii,et al.  Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. , 2004, Journal of hepatology.

[30]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.